Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_assertion type Assertion NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_head.
- NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_assertion description "[We now show that the combination of A-357300 with cyclophosphamide at the maximal tolerated dose sustained tumor regression with a T/C at day 48 of 0.16 (P < 0.001) in the CHP-134 xenograft model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_provenance.
- NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_assertion evidence source_evidence_literature NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_provenance.
- NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_assertion SIO_000772 15814649 NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_provenance.
- NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_assertion wasDerivedFrom befree-20150227 NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_provenance.
- NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_assertion wasGeneratedBy ECO_0000203 NP863705.RA1bytVrd-UDr7N4B4FgvG178rbx8-HBgg2IJGTW05SSI130_provenance.